Biopharma Week in Review - Jul 29, 2024
Last week, IONS matched Ultragenyx’s Angelman benefit, with maybe better safety. PFE and SGMO had approvable gene therapy results in hemophilia A,...
251 Views
Another Bear Market Rally Brewing?; Stick With Biotech and Construction/Engineering Names
Early indications suggest another bear market rally in $SPX, and potentially that the lows are in, helped by short-term bearish engulfing patterns...
410 Views
S&P 500, Nasdaq 100 Testing Key Resistance Levels; Pause Likely; Buying Biotech
$SPX is testing important resistance in the 4165-4180 area, the same resistance level we were monitoring in early June before the market tumbled 13...
438 Views
S&P 500 and S&P 600 Testing Resistance...Still
The S&P 500 is beginning to come off of short-term overbought extremes, consolidating near the confluence of key overhead resistance and the...
295 Views
Innovation to Help Maintain HIV Franchise Market Share and Weather Harsh Domestic Market Conditions
Continuous innovation at HIV Franchise to not only help defend market share…. Concerns about competition from Gilead Sciences Inc (GILD US)'s,...
256 Views